PickAlpha Evening Insights | 2026-04-17 - Trade Ideas For The Next Trading Day
• Stocks mixed as legal and biotech headlines set the tone while rates held relatively steady, big story federal court ruling. • After hours: Nuvalent detailed zidesamtinib data and reiterated Sep. 1
Market Wrap
Market Recap — Legal clarity for oil defendants and fresh AACR data drove sector rotation into defensives and selective biotech names; State Street’s beat underscored fee resilience and cyclical banking strength. The Supreme Court’s 8-0 jurisdiction win for oil companies shifted litigation risk perceptions for majors like Chevron ($CVX), while oncology posters from multiple companies lifted hopes for pipeline upside, notably Zymeworks ($ZYME). Earnings and data flow kept investors re-pricing service providers and specialty biotechs, with State Street ($STT) reporting stronger Q1 results. Nuvalent’s after-hours update added a near-term regulatory catalyst to watch ($NUVL).
Intraday — Early biotech poster releases from Cogent highlighted selectivity and brain-penetrant data for pipeline assets (Cogent ($COGT)), and State Street reported Q1 net income of $764 million, or $2.49 per share, citing higher fee and custody activity (State Street ($STT)). Midday, the U.S. Supreme Court’s 8-0 decision favored oil companies in venue disputes, reducing legal overhang for majors such as Chevron ($CVX) and Exxon ($XOM). Late-session AACR detail from Zymeworks showed a 30% pathological complete response at six weeks for zanidatamab in early HER2-positive breast cancer, supporting upside optionality for partners (Zymeworks ($ZYME), Jazz ($JAZZ)).
After Hours — Nuvalent released new AACR materials showing zidesamtinib activity, including responses in ROS1 G2032R-mutant tumors and intracranial complete responses, and reiterated the FDA PDUFA date of Sept. 18, 2026 (Nuvalent ($NUVL)); the update creates a clear near-term regulatory timeline. Biotech peers that posted AACR data intraday, like Zymeworks ($ZYME), remain in focus as investors weigh comparative clinical readthroughs.
Trade Ideas For The Next Trading Day
1/2 Long $ENTA — Intraday (0–1d) • Other
Plan: If ESCMID oral reiterates >=7 days symptom-resolution improvement, long $ENTA at next regular-session open; hold next 1–3 sessions.
Enanta’s Apr. 18 ESCMID oral session on zelicapavir in high-risk adults with RSV is slated to provide Phase 2b RSVHR detail previously described as about a one-week improvement in complete symptom resolution, lower hospitalization rate, and new exposure-multiple analyses over EC90. A reiterated ~one-week benefit is an easy headline for differentiation and later-stage/partnering value, making this a near-term catalyst for ENTA sentiment.
Enanta’s Apr. 18 IMMUNOLOGY2026 poster on STAT6 inhibitor EPS-3903 focuses on preclinical pharmacokinetics it says support sustained STAT6 inhibition with once-daily oral dosing in humans, within a broader four-poster package (tolerability, selectivity, asthma-model efficacy, PK). A credible once-daily PK narrative can raise confidence in development practicality for an oral STAT6 program, potentially supporting a near-term pipeline multiple expansion.
Risk: Exit if symptom-resolution improvement is under 7 days. • Valid until 2026-04-24 20:37 ET
Trade credibility: actionability ★★★☆☆ | timeliness ★★★☆☆ | clarity ★★★★☆
2/2 Long $ZYME — Intraday (0–1d) • Other
Plan: If AACR oral reiterates >=30% pCR, go long $ZYME at next regular-session open; hold next 1–3 sessions.
Jazz/Zymeworks have an Apr. 18 AACR oral for Phase 2 NeoZanHER in early-stage HER2+ breast cancer, with pre-released six-week data showing statistically significant tumor shrinkage and 30% pCR (6 patients). Confirmation at/above that pCR level would strengthen the label-expansion narrative for zanidatamab beyond biliary tract cancer, supporting near-term rerating in the more program-levered ZYME.
Risk: Exit if presentation reports pCR below 30%. • Valid until 2026-04-24 20:37 ET
Trade credibility: actionability ★★★☆☆ | timeliness ★★★☆☆ | clarity ★★★☆☆